Literature DB >> 28125819

Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.

Martín Granados-García1, José Luis Aguilar-Ponce, Federico Maldonado-Magos, Jaime G De la Garza-Salazar.   

Abstract

We review clinical trials of squamous cell carcinoma of the head and neck (SCCHN) to address the current and potential uses of cetuximab (CTX). PubMed was reviewed to identify papers published between 2010 and 2016. The search terms used were "cetuximab" and "head and neck cancer." A total of 634 articles were identified. Phase II or III studies with CTX in patients with advanced SCCHN without treatment or with recurrent/metastatic tumors were selected. Forty-six registries were obtained. Information was critically reviewed and relevant information presented. As definitive treatment of advanced squamous cells carcinomas and as palliative treatment of recurrent/metastatic disease, CTX alone or associated with chemotherapy and/or radiotherapy is an alternative to chemoradiotherapy because of its distinct and favorable toxicity profile.
© 2017 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28125819     DOI: 10.1159/000455891

Source DB:  PubMed          Journal:  ORL J Otorhinolaryngol Relat Spec        ISSN: 0301-1569            Impact factor:   1.538


  2 in total

1.  A comprehensively revised strategy that improves the specific activity and long-term stability of clinically relevant 89Zr-immuno-PET agents.

Authors:  Nikunj B Bhatt; Darpan N Pandya; Stephanie Rideout-Danner; Howard D Gage; Frank C Marini; Thaddeus J Wadas
Journal:  Dalton Trans       Date:  2018-09-04       Impact factor: 4.390

2.  Case report of penile cancer recurrence treated with cetuximab combined with anlotinib.

Authors:  Shuang Dai; Yan-Yang Liu; Tao Liu; Yu Zhang; De-Yun Luo
Journal:  Clin Case Rep       Date:  2022-02-15
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.